Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium and Vilanterol Safety in COPD (COPD nDPI)
NCT01316887Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of umeclidinium in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jan 2011; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01316887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01316887.